Bree C. Peterson

Counsel, London



Bree Peterson is a US qualified counsel in the Firm's Capital Markets group in London.

Bree is experienced in advising on a range of cross-border capital markets transactions, with particular experience in SEC registered offerings, Rule 144A/Reg S offerings, cross-border PIPE transactions and other public and private financings. Bree's practice also includes advising sovereign governments and investment banks on SEC registered bond offerings. Bree advises companies and depositary banks in connection with a wide variety of depositary receipt matters.  Bree has particular experience in capital markets matters for companies in the technology and biotech/life sciences sectors.

Bree also has experience in cross-border mergers and acquisitions, Exchange Act reporting and complex global corporate and tax reorganizations.

Prior to joining White & Case, Bree practiced in prominent international law firms in London and Minneapolis.

Bars and Courts
University of St. Thomas
International Relations
University of San Diego


Equity capital markets

  • Morgan Stanley, J.P. Morgan and Citigroup, as representatives of the underwriters, on JSC's US$1 billion US IPO on Nasdaq. operates a two-sided Super App business model, including payments, marketplace and fintech solutions for consumers and merchants.
  • Hespiburada, a leading Turkish e-commerce company, in its US$780 million US IPO on Nasdaq. The transaction was the first IPO by a Turkish company on Nasdaq.
  • Morgan Stanley, Goldman Sachs, Credit Suisse, VTB Capital, B of A Merrill Lynch, and Sberbank in connection with the US$220 million US IPO of HeadHunter Group PLC, a leading online recruitment platform in Russia and the CIS, on Nasdaq and advised the underwriters in subsequent follow-on equity offerings for HeadHunter Group.
  • Proposed US registered IPOs in the EdTech, FoodTech, FinTech/Payments and online media industries.
  • Represented placement agents, including Guggenheim Securities, Jefferies, H. C. Wainwright, Cantor Fitzgerald, Danske Bank, Oddo BHF, Baader Bank, Arctic Securities and Bryan Garnier & Co, in cross border PIPE transactions for several publicly listed European biotech/life sciences companies, including:
    • Basilea Pharmaceutica Ltd, listed on the SIX Swiss Exchange;
    • Acacia Pharma Group plc, listed on Euronext Brussels;
    • Orphazyme A/S, listed on Nasdaq Copenhagen;
    • Valneva SE, listed on Euronext Paris;
    • Medigene AG, listed on the Frankfurt Stock Exchange;
    • BerGenBio ASA, listed on the Oslo Stock Exchange;
    • Transgene SA, list on Euronext Paris;
    • Gensight Biologics S.A., listed on Euronext Paris;
    • Onxeo S.A., listed on Euronext Paris and Nasdaq Copenhagen;
    • Zealand Pharma A/S, listed on Nasdaq Copenhagen and Nasdaq US;
    • Newron Pharmaceutical S.p.A., listed on the SIX Swiss Exchange;
    • Nicox S.A., listed on Euronext Paris;
    • Oryzon Genomics S.A., listed on the Spanish stock exchanges; and
    • Mithra Pharmaceuticals SA/NV, listed on Euronext Brussels.
  • Summit Therapeutics plc, an AIM-listed clinical stage drug discovery and development company, in its US IPO on Nasdaq.*
  • Leerink Partners, Deutsche Bank and JMP Securities as underwriters in connection with the US IPO of ProQR Therapeutics N.V., a biopharmaceutical company engaged in development of RNA-based therapeutics, on Nasdaq.*
  • uniQure N.V., a gene therapy company, in its US IPO on Nasdaq.*

SEC-registered sovereign bonds

  • The State of Israel on its largest ever international bond offering. The US$8 billion SEC-registered bond offering was comprised of US$2 billion 5.375% bonds due 2029, US$3 billion 5.500% bonds due 2034 and US$3 billion 5.750% bonds due 2054.
  • The State Treasury of the Republic of Poland on its largest bond issuance in the US dollar market. The US$8 billion SEC-registered bond offering was comprised of US$1.5 billion 4.625% bonds due 2029; US$3 billion 5.125% bonds due 2034; and US$3.5 billion 5.500% bonds due 2054.
  • Absa Bank, Deutsche Bank, HSBC, Nedbank and Rand Merchant Bank in connection with the Republic of South Africa's dual tranche issuance of US$1.4 billion in 5.875% Notes due 2032 and US$1.6 billion in 7.300% Notes due 2052.

Debt capital markets and restructurings

  • Bidvest Group (UK) Plc, a wholly owned subsidiary of The Bidvest Group Limited, on its offering of US$800 million 3.625% Senior Notes due 2026.
  • ADES International, a leading provider of offshore and onshore oil and gas drilling and mobile production services in the Middle East and Africa, in connection with the issuance of US$325 million 8.625% Senior Secured Notes due 2024.
  • IHS Towers, one of the largest independent owners, operators and developers of shared communications infrastructure in the world, on its US$500 million and US$800 million dual-tranche bond issue and on its US$500 million (equivalent) US$ and Nigerian Naira pari passu senior credit facilities agreement, which together provided IHS Towers with an aggregate US$1.8 billion (equivalent).

Depositary receipt matters

  • Deutsche Bank, as depositary bank, on over 25 U.S. IPOs of foreign companies listing American Depositary Shares on a US national securities exchange and a number of public and private follow-on financings, as well as other transactions using ADRs or GDRs, including, among others:
    • Li Auto, IPO on Nasdaq, listing on HK stock exchange, issuance of convertible bonds;
    • Lepu Medical Technology (Beijing) Co., Ltd., listing on the SIX Swiss Exchange;
    • DiDi Global Inc., IPO on the New York Stock Exchange;
    • Pinduoduo, IPO on Nasdaq, issuances of convertible bonds;
    • Bilibili Inc., IPO on Nasdaq Global Select Market and subsequent follow-on and issuance of convertible bonds
  • Experience in depositary receipt program establishment (Level I, Level II and Level III ADR programs and GDR programs), program transfers, program terminations, DR restricted securities programs and resales issues, pledges and DR aspects of margin loans, SPAC and de-SPAC depositary receipt matters, depositary liability questions and risk analysis, multi-exchange DR listings and share migrations, DR in-kind distributions, depositary receipt related ESOP/LTIP matters, among other things.

*Matters prior to joining White & Case